A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

UCB

Status: Completed

Conditions: Plaque Psoriasis

Treatments: Drug: Certolizumab pegol

Study type: Observational

Funder types: Industry

Identifiers

NCT04053881

PS0026

Details and patient eligibility

About

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Enrollment: 412 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient is ≥18 years of age at observational point 1
• The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice
• The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care
• The patient must be newly prescribed with certolizumab pegol
• If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study

Exclusion criteria

Not applicable

Trial design

412 participants in 1 patient group

Certolizumab pegol

Description:

Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).

Treatment:

Drug: Certolizumab pegol